FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma By Ogkologos - September 30, 2026 56 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IGNYTE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by... January 23, 2026 EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab June 5, 2025 EMA Recommends Extension of Indications for Daratumumab June 10, 2021 First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield... December 4, 2023 Load more HOT NEWS Sotorasib Shows Promising Activity and Acceptable Safety in Patients with Previously... ESMO launches new principles for humanising scientific reporting to strengthen the... FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... How to Get Started With Exercising at Home During Cancer
